Mona El-Hashimy

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

Angelo Di Leo, Stephen Johnston, Keun Seok Lee et al. · The Lancet Oncology · 2017 · 381 citations

Medicine, Oncology, Pharmacology +16

Acute Postchallenge Hyperinsulinemia Predicts Weight Gain: A Prospective Study

Ronald J. Sigal, Mona El-Hashimy, Blaise C. Martin et al. · Diabetes · 1997 · 153 citations

Medicine, Endocrinology, Physiology +7

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Hope S. Rugo, Kathleen I. Pritchard, Michael Gnant et al. · Annals of Oncology · 2014 · 127 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer

Nicoletta Colombo, E. Kutarska, Meletios Α. Dimopoulos et al. · Journal of Clinical Oncology · 2012 · 123 citations

Medicine, Oncology, Pharmacology +15

Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2

Michael Gnant, José Baselga, Hope S. Rugo et al. · JNCI Journal of the National Cancer Institute · 2013 · 98 citations · Full text

Medicine, Oncology, Pharmacology +17